CytomX Therapeutics, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019. Financial statements are unaudited. Unless noted, amounts below are in U.S. dollars and millions.
Business context
CytomX is a clinical-stage oncology biotechnology company developing antibody therapeutics using its Probody platform. It has no approved products and no product-sales revenue; reported revenue comes primarily from collaboration and licensing arrangements. Its clinical programs include CX-072, CX-2009 and partnered CX-2029, with BMS advancing a separate Probody candidate.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 or prior date |
|---|---|---|
| Revenue | $29.5 | $14.2 |
| Research and development expense | $36.4 | $22.5 |
| General and administrative expense | $9.7 | $7.4 |
| Loss from operations | $(16.6) | $(15.6) |
| Net loss | $(14.1) | $(15.5) |
| Net loss per share, basic and diluted | $(0.31) | $(0.40) |
| Operating cash flow | $(39.0) | $(14.6) |
Revenue rose $15.3 million, primarily because CytomX recognized $17.4 million of previously deferred BMS revenue after BMS ended work on certain targets. BMS contributed $25.5 million of Q1 2019 revenue. R&D expense increased $13.9 million, including a $5.0 million charge for acquired technical know-how, higher clinical and laboratory costs, and increased personnel expense. G&A increased $2.3 million. Revenue is collaboration-based, so conventional product gross-margin comparisons are not meaningful.
At March 31, 2019, cash and cash equivalents were $190.4 million and short-term investments were $206.2 million, totaling $396.6 million. Total current assets were $405.1 million and current liabilities were $96.2 million. The company reported no borrowings or debt balance in the balance sheet. Total liabilities were $321.9 million, including $248.5 million of deferred revenue and $29.6 million of operating lease liabilities. Accumulated deficit was $329.1 million. Cash, cash equivalents and restricted cash declined $57.2 million during the quarter.
Material changes and unusual items
- BMS terminated preclinical activities on three targets in Q1. CytomX recognized $17.4 million of related deferred revenue for two targets for which it concluded it had no further obligations; it continues to recognize revenue for another target still being developed.
- No deferred-revenue additions were recorded in Q1. Total deferred revenue fell from $278.0 million at December 31, 2018 to $248.5 million at March 31, 2019.
- CytomX expensed $5.0 million for technology know-how acquired in January 2019, rather than capitalizing it, because it relates to discovery-stage projects.
- The company adopted lease accounting standard ASC 842 on January 1, 2019, recording a right-of-use asset and lease liability. At March 31, lease liabilities totaled $29.6 million; adoption was not expected to materially affect results or cash flows.
- After quarter-end, CytomX amended its UCSB license agreement, issued UCSB 150,000 shares, and agreed to a $1.0 million upfront payment and annual maintenance fees of $750,000 through 2031. The filing says the amendment also revises certain sublicense-revenue terms.
Outlook, commentary and principal risks
Management stated that existing capital resources were expected to fund planned operations into 2021, while also stating that additional funding will be needed. The company expects significant continuing losses and R&D spending; spending and collaboration revenue may vary with clinical progress, trial costs, milestones and partner decisions. No product revenue is expected in the foreseeable future.
- Clinical development remains early and uncertain. Safety or efficacy findings, regulatory requirements, enrollment delays or trial outcomes could delay or halt programs. The filing notes reported Grade 3/4 treatment-related adverse events in CX-2009 and anti-drug antibodies observed in CX-072; early data do not establish future safety or efficacy.
- CytomX relies on collaborators, contract research organizations and third-party manufacturers. It highlighted the ongoing transfer of CX-2009 manufacturing after ImmunoGen closed a clinical manufacturing facility, as well as broader supply and scale-up risks.
- Collaborators control important development decisions. BMS’s target discontinuations and Pfizer’s earlier termination illustrate the risk that programs may be stopped, reducing potential milestones and royalties.
- The company has no manufacturing capabilities of its own and may need further capital. Financing may be unavailable or dilutive, or may require restrictive terms.
- Other disclosed risks include competition, intellectual-property challenges, regulatory and reimbursement uncertainty, and reliance on a novel technology platform.
Management reported that disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2019. No material change in internal control over financial reporting was reported for the quarter.
Investor verification points
- Confirm the composition and liquidity of the $396.6 million cash-and-investment balance, quarterly cash use, and assumptions underlying the projected runway into 2021.
- Assess how much Q1 revenue depended on the one-time $17.4 million BMS deferred-revenue acceleration, and the timing and conditions for recognizing the remaining $248.5 million of deferred revenue.
- Review clinical-trial updates for CX-072, CX-2009 and CX-2029, particularly safety, anti-drug antibodies, enrollment and manufacturing supply.
- Evaluate the financial and intellectual-property effects of the UCSB amendment, including the $750,000 annual fee through 2031 and revised sublicense terms.
- Monitor collaboration partner decisions, future financing needs and potential dilution; the filing provides no specific financing amount or detailed future expense guidance.